open access

Vol 4, No 3 (2013)
Review paper
Published online: 2013-11-13
Get Citation

Management of tyrosine kinase inhibitors adverse effects in patients with chronic myelogenous leukemia

Krzysztof Lewandowski
Hematologia 2013;4(3):206-218.

open access

Vol 4, No 3 (2013)
REVIEW ARTICLES
Published online: 2013-11-13

Abstract

Introduction of tyrosine kinase inhibitors (TKI) to the treatment of chronic myelogenous leukemia change the prognosis of this group of patients. Results of the study performed confirmed that TKI treatment tolerance in most of the patients is good. Five-years follow-up of IRIS study revealed that 4.9% patients discontinued first-line treatment with imatinib due to adverse effects appearance. Similarly, good tolerance profile was confirmed in a case of 2-generation of TKI — nilotinib (NILO) and dasatinib (DAZA). Mostly, side effects appearance is observed in first months/year of TKI treatment. Rarely, its occurrence leads to discontinuation of the treatment applied. Most frequently, non-hematologic toxicity is observed (nausea, vomiting, diarrhea, skin changes including macula-popular rush, utricaria, fotosensibilisation, and superficial edemas, fluid retention, muscle crump, headache) or hematologic toxicity (granulocytopenia, thrombocytopenia, anaemia). Rarely, TKI administration leads to hyperglycemia, rise in blood amylase activity or bilirubin concentration, and appearance the symptoms of peripheral artery occlusive disease (NILO) orpericardial/pleural effusion, pulmonary artery hypertension (DAZA). When they are noted, interactions with other drugs interfering with metabolism of TKI and increasing its toxicity should be excluded. Monitoring and recommendations concerning TKI related adverse effect treatment is a topic of this paper.

Abstract

Introduction of tyrosine kinase inhibitors (TKI) to the treatment of chronic myelogenous leukemia change the prognosis of this group of patients. Results of the study performed confirmed that TKI treatment tolerance in most of the patients is good. Five-years follow-up of IRIS study revealed that 4.9% patients discontinued first-line treatment with imatinib due to adverse effects appearance. Similarly, good tolerance profile was confirmed in a case of 2-generation of TKI — nilotinib (NILO) and dasatinib (DAZA). Mostly, side effects appearance is observed in first months/year of TKI treatment. Rarely, its occurrence leads to discontinuation of the treatment applied. Most frequently, non-hematologic toxicity is observed (nausea, vomiting, diarrhea, skin changes including macula-popular rush, utricaria, fotosensibilisation, and superficial edemas, fluid retention, muscle crump, headache) or hematologic toxicity (granulocytopenia, thrombocytopenia, anaemia). Rarely, TKI administration leads to hyperglycemia, rise in blood amylase activity or bilirubin concentration, and appearance the symptoms of peripheral artery occlusive disease (NILO) orpericardial/pleural effusion, pulmonary artery hypertension (DAZA). When they are noted, interactions with other drugs interfering with metabolism of TKI and increasing its toxicity should be excluded. Monitoring and recommendations concerning TKI related adverse effect treatment is a topic of this paper.
Get Citation

Keywords

chronic myelogenous leukemia, tyrosine kinase inhibitors, adverse effects

About this article
Title

Management of tyrosine kinase inhibitors adverse effects in patients with chronic myelogenous leukemia

Journal

Hematology in Clinical Practice

Issue

Vol 4, No 3 (2013)

Article type

Review paper

Pages

206-218

Published online

2013-11-13

Bibliographic record

Hematologia 2013;4(3):206-218.

Keywords

chronic myelogenous leukemia
tyrosine kinase inhibitors
adverse effects

Authors

Krzysztof Lewandowski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.